Form 4: Cytokinetics Director Wendell Wierenga Acquires Shares in Lieu of Cash Retainer

Director Wendell Wierenga acquired 118 shares of Cytokinetics Inc. common stock in lieu of a cash retainer payment on October 1, 2024.

Summary

• On October 1, 2024, Wendell Wierenga, a director of Cytokinetics Inc., acquired 118 shares of common stock.
• The acquisition was made in lieu of a cash retainer payment.
• The price per share was $52.6.
• Following the transaction, Wierenga directly owns 24,559 shares of Cytokinetics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (stock award in lieu of cash). It doesn't strongly indicate positive or negative sentiment about the company's prospects.

Positives

• The director's acquisition of shares, even in lieu of cash, could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This type of transaction, where directors receive stock in lieu of cash compensation, is relatively common in the biotech industry, especially for companies looking to conserve cash.

Comparison to Industry Standards

• Stock awards in lieu of cash compensation are a common practice among biotech companies, especially smaller ones, to conserve cash.
• Comparing Cytokinetics' executive compensation structure with peers like BioMarin, Vertex, or Amgen would provide a broader context.
• Analyzing the percentage of equity-based compensation versus cash compensation for Cytokinetics' directors compared to industry averages would be insightful.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.

Key Dates